A major clinical setback removed a potential blockbuster drug from Alnylam’s pipeline and led to a collapse in the company’s share price. . Shares of the RNAi-focused biotech utterly collapsed, falling by nearly 60% during the year, according to data from S&P Global Market Intelligence .